ArticleAIDS (London, England)2026
A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo investigate the novel 3-in-one long-acting injectable product composed of tenofovir alafenamide (TAF), dolutegravir (D), and lamivudine (L), as a complete TAF-DL product for pediatric HIV treatment.
designTAF-DL sterile injectable product is assembled with three HIV drugs and amphipathic lipids. It is built on the drug-combination-nanoparticle (DcNP) platform via a well defined manufacturing process. Plasma concentrations for all three drugs were determined in 12 juvenile non-human primates (NHP, Macaca nemestrina ) following subcutaneous administration. Safety parameters monitored.
resultsFollowing a single dose of TAF-DL-in-DcNP , all drugs exhibited long-acting cell-and-plasma profiles in juvenile NHP for 8 weeks. Time-to-peak occurred within 24 h for all drugs. Compared to free-soluble counterpart, DcNP formulation enhanced the half-life of TAF, D, and L by 23-fold, 5.8-fold, 8.3-fold, respectively, and area under the curve (AUC) by 41-fold, 18-fold, 3.1-fold. Cell targeting enabled by DcNP is noted as higher intracellular PBMC versus plasma concentration of TAF, tenofovir (T), D, L in NHP dosed with TAF-DL-in-DcNP product. Safety assessment in 12 juvenile NHPs noted no injection-site reactions, or change in weight, complete blood count, and serum chemistries over 8 weeks.
conclusionCurrent 3-HIV oral drugs, TAF-DL is successfully transformed into a novel, single long-acting injectable product that may support once every 2 month dosing. TAF-DL-in-DcNP enhanced HIV host-lymphocyte drug exposure. With less than 24 h to reach Cmax , the all-in-one product may overcome the need for an oral lead-in typically required to initiate LA injectables. TAF-DL-in-DcNP product appears to be safe in juvenile NHPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.